Bavarian Nordic Reports Preliminary Financial Results for 2020
- Revenue and EBITDA in line with guidance for 2020. Year-end cash position better than guided for 2020
COPENHAGEN, Denmark, January 28, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today reported preliminary, unaudited financial results for 2020 in line with or better than the Company’s most recent guidance.
- Revenue for the full year is expected at approximately DKK 1,852 million, comprised of DKK 1,082 million from combined sale of Rabipur/RabAvert and Encepur, DKK 704 million from US Government sale, including JYNNEOS revenue and contract work, and finally DKK 66 million from the milestone payment from Janssen (Ebola vaccine approval).
- The operating result (EBITDA) is expected at approximately DKK 740 million, including other operating income of DKK 628 million from the sale of Priority Review Voucher.
- Cash position at year-end was approximately DKK 1,670 million, excluding unutilized credit facilities of DKK 244 million.
|DKK million||FY 2020 |
|FY 2020 |
|FY 2020 |
|Securities, cash and cash equivalents||1,350||1,600||1,670|
Revenue in 2020 significantly increased over 2019 as a result of the commercial transformation of Bavarian Nordic following the acquisition of two commercial vaccines, Encepur and Rabipur/RabAvert. COVID-19 negative impact on Encepur and Rabipur/RabAvert revenue was limited to approximately DKK 200 million by strong brand performance in key markets and largely off-set by better than originally expected JYNNEOS revenue. A USD weakening against DKK had some negative impact on RabAvert revenue in the last two months of 2020.
EBITDA came in slightly better than guided due to continued tight focus on cost and profitability.
The year-end cash position exceeded guidance due to phasing of ongoing investments and working capital movements. This was achieved without draw-down of existing credit facilities of DKK 244 million. Due to the strong cash position the draw-down was deferred to 2021.
“We are very pleased to deliver results in line with or better than the original guidance from February 2020 when no-one really understood the full-scale dramatic effect of COVID-19 on the world. These results have been achieved by good market performance in key markets, by the governmental business performing better than originally anticipated and by keeping a tight focus on profitability and cash,” said Paul Chaplin, President and CEO of Bavarian Nordic.
Bavarian Nordic will publish its annual report for 2020 on March 12, 2021, including financial guidance for 2021.
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Our commercial product portfolio furthermore contains the market-leading vaccine Rabipur®/RabAvert® against rabies and Encepur® against tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, MVABEA®, which is licensed to Janssen. For more information visit www.bavarian-nordic.com.
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, firstname.lastname@example.org, Tel: +1 781 686 9600
Company Announcement no. 01 / 2021
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Annual General Meeting announcement24.2.2021 18:41:30 CET | Press release
February 24, 2021 SBM Offshore announces that the agenda of the Annual General Meeting (AGM) and the invitation for shareholders to attend the AGM have now been published on the Company’s website. The AGM will be held virtually on April 7, 2021 at 14.30 Central European Time. Corporate Profile The Company’s main activities are the design, supply, installation, operation and the life extension of floating production solutions for the offshore energy industry over the full lifecycle. The Company is market leading in leased floating production systems, with multiple units currently in operation. As of December 31, 2020, the Company employed approximately 4,570 people worldwide spread over offices in our key markets, operational shore bases and the offshore fleet of vessels. SBM Offshore N.V. is a listed holding company headquartered in Amsterdam, the Netherlands. It holds direct and indirect interests in other companies. Where references are made to SBM Offshore N.V. and /or its subsidiar
AMG Advanced Metallurgical Group N.V. Reports Full Year and Fourth Quarter 2020 Results24.2.2021 18:00:00 CET | Press release
Coronavirus Update As of today, out of over 3,000 employees we have 3 active confirmed coronavirus cases globally. AMG has zero current COVID hospitalization cases. AMG has not experienced any coronavirus related fatalities, and our current cases have not resulted in a facility closure or operational interruption. AMG continues to implement preventive measures such as practicing social distancing, remote working when possible, and restrictions on travel to protect the health and safety of our employees. Strategic Highlights The construction of AMG’s second ferrovanadium plant in Zanesville, Ohio is proceeding as planned. As of December 31, 2020, AMG has committed $206 million in construction and engineering contracts for the project.AMG Brazil has entered into an Exclusive Cooperation Agreement (“ECA”) with one of its major customers for lithium concentrates. The ECA provides for AMG Brazil to supply 200,000 DMT over a 5-year supply term, which will be obtained from an expansion (targe
Golar LNG Partners LP Common Unitholders Approve Merger at Special Meeting24.2.2021 17:55:15 CET | Press release
Golar LNG Partners LP announces that at a special meeting held today, the holders of common units representing limited partner interests of Golar LNG Partners LP (Nasdaq: GMLP) (“GMLP”) voted on and approved the Agreement and Plan of Merger (the “Merger Agreement”), dated as of January 13, 2021, by and among GMLP, Golar GP LLC, New Fortress Energy Inc. (“NFE”), Lobos Acquisition LLC and NFE International Holdings Limited, and the merger contemplated thereby (the “Merger”). Pursuant to the Merger Agreement NFE has agreed to acquire all of the outstanding common units and general partner units of GMLP for $3.55 per unit in cash. The Merger is expected to close in the first half of 2021. As previously announced, the closing of the merger is conditioned upon receipt of a number of approvals and consents. FORWARD-LOOKING STATEMENTS This press release contains certain forward-looking statements concerning future events. Forward-looking statements include, without limitation, any statement th
LIDDS files patent application for method to treat brain cancer with intratumoral depot injections24.2.2021 17:19:34 CET | Press release
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that a patent application related to NanoZolid® for treatment of brain cancers was filed to the European patent office. The patent application relates to a method to treat brain cancer with intratumoral depots providing a controlled drug release at the tumor site. Advances in treatments of malignant brain tumors have only modestly improved survival rates of patients. LIDDS can with the NanoZolid® technology expand its platform to brain cancer by circumventing the blood-brain barrier and to increase the drug distribution within the tumor area. “It is with excitement that we file a patent in this important area with a large unmet medical need,” said Monica Wallter, CEO of LIDDS. “Our favorable preclinical results on the NanoZolid® carrier in brain tissue, together with the drug release characteristics that we can obtain with our technology, form the basis for this invention. I am hopeful that this development and potential commercializati
SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING24.2.2021 16:20:00 CET | Press release
Bid date, 2021-02-26Bid Submission Date2021-02-26Bid times10.30-11.00 (CET/CEST) on the Bid dateOffered Amount50 billion SEKMaximum Permitted Bid Volume12.5 billion SEK from an individual bidderSettlement Date2021-03-02Minimum Permitted Bid Volume10 million SEK per bidFinal Repayment Date2025-03-03Maximum Allocation25 per cent of Offered AmountAllocation TimeNot later than 11.30 (CET/CEST) on the Bid dateRepayment Date2022-03-02Option Repayment Date 12023-03-02Option Repayment Date 22024-03-04Interest rateThe Riksbank´s applicable repo rateAdditional interest rate0.10 per centConfirmation of bids to email@example.com Stockholm, 2021-02-24 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.
Auction details treasury bills24.2.2021 16:20:00 CET | Press release
Auction date March 3, 2021 Maturity date Issue volume, SEK million Days (Act/360) ISIN code 2021-06-16 7,500 103 SE00145559912022-03-16 7,500 376 SE0015659529 Settlement date March 5, 2021 Bids have to be entered by 11.00 on March 3, 2021 Bid only through dealers approved by the Swedish National Debt Office For more information, please contact: The funding desk + 46 8 613 4780 Fo@riksgalden.se
JETEX MAKES FLYING WITH A REDUCED CARBON FOOTPRINT POSSIBLE24.2.2021 12:45:47 CET | Press release
Dubai, United Arab Emirates, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Jetex customers are now able to choose to fly with a reduced carbon footprint from six key global locations following an agreement with Shell. This demonstrates how general aviation service providers can support the International Air Transport Association (IATA) and its commitment to reducing the industry’s carbon emissions by 50% by 2050. Jetex, an award-winning global leader in executive aviation, is fully aware of its responsibility towards the natural environment and to future generations, and pursues a comprehensive environmental strategy. In today’s world, private aviation is a vital global catalyst for growth, providing access to markets, supporting jobs and promoting travel recovery. In addition to its many positive economic effects, though, air transport contributes to the production of carbon emissions. In response, Jetex is working with Shell to offer customers an option to offset the carbon emissions of their ai